Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
European Urology
|
April 11, 2020
"PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older
Sigrid V Carlsson, James A Eastham, E David Crawford, et al.
The Prostate
|
March 5, 2020
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
Neal D Shore, Emmanuel S Antonarakis, Michael S Cookson, et al.
The Journal of Urology
|
October 22, 2020
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data
E David Crawford, Jason M Hafron, Scott T Tagawa, et al.
The Journal of Urology
|
October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data
E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
European Urology
|
April 11, 2020
"PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older
Sigrid V Carlsson, James A Eastham, E David Crawford, et al.
The Prostate
|
March 5, 2020
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
Neal D Shore, Emmanuel S Antonarakis, Michael S Cookson, et al.
The Journal of Urology
|
October 22, 2020
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data
E David Crawford, Jason M Hafron, Scott T Tagawa, et al.
The Journal of Urology
|
October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data
E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Page
of 1